Cho, K. Y., Nakamura, A., Omori, K., Takase, T., Miya, A., Yamamoto, K., . . . Miyoshi, H. (2020). Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone. J Diabetes Investig.
Chicago ZitierstilCho, Kyu Yong, et al. "Favorable Effect of Sodium–glucose Cotransporter 2 Inhibitor, Dapagliflozin, On Non‐alcoholic Fatty Liver Disease Compared With Pioglitazone." J Diabetes Investig 2020.
MLA ZitierstilCho, Kyu Yong, et al. "Favorable Effect of Sodium–glucose Cotransporter 2 Inhibitor, Dapagliflozin, On Non‐alcoholic Fatty Liver Disease Compared With Pioglitazone." J Diabetes Investig 2020.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.